Navigation Links
Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Date:12/10/2009

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through January 15, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. 


Contact Information:

Peter Dworkin                  Laura Lindsay
Investor Relations             Media Relations
914.345.7640                   914.345.7800
peter.dworkin@regeneron.com    laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
(Date:6/18/2013)... , June 18, 2013  Cataracts are the leading ... American Association of Ophthalmology, aging is the leading cause ... the eye,s natural lens. 22 million Americans age 40 ... Boomers continue to age, that number will increase over ... of iPhones, iPads, smart-phones and computers, the demographic of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... (NYSE: LLY ) will present data from more ... American Society of Clinical Oncology (ASCO) in Chicago, Ill., from ... Phase III study of an ALIMTA-based continuation maintenance regimen for ... data will be included in the ASCO-sponsored press briefing the ...
... Systems Inc. (OTCBB: PLCSF), a company focused on innovative ... three- month period ended March 31, 2011. These results ... the sale of its transmyocardial revascularization (TMR) business to ... from the TMR business for the first quarter of ...
Cached Medicine Technology:Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO 2PLC Systems Reports First Quarter 2011 Results 2PLC Systems Reports First Quarter 2011 Results 3PLC Systems Reports First Quarter 2011 Results 4PLC Systems Reports First Quarter 2011 Results 5PLC Systems Reports First Quarter 2011 Results 6PLC Systems Reports First Quarter 2011 Results 7
(Date:6/18/2013)... 2013 The Drug Delivery Partnering Terms ... to the drug delivery partnering deals and agreements entered ... The report provides a detailed understanding and analysis of ... The majority of deals are discovery or development stage ... right to license the license drug delivery technology. These ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Senior drug regulatory ... on June 25 to discuss—for the first time in the ... getting drugs through the regulatory process in a timely manner. ... evaluation will share respective best practices and processes in drug ... Strait panel at the DIA 2013 49th Annual ...
(Date:6/18/2013)... Biomet hip lawsuit claims ... in a multidistrict litigation in U.S. District Court, Northern ... to court records, the litigation’s most recent status conference ... Court also convened a motions hearing and a tutorial ... Biomet hip replacement litigation. The proceeding’s next Status ...
(Date:6/18/2013)... Dallas, TX (PRWEB) June 18, 2013 ... Tebbetts, launched his new website, thebestbreast.com, showcasing his ... provides women with information about his surgical method ... , Outlined on his website, Dr. Tebbetts ... Unlike the traditional methods, Dr. Tebbetts’ method does ...
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
Breaking Medicine News(10 mins):Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:SimuCase avatars advance speech-language pathology training 2
... RATON, Fla., Sept. 26 Biomedtex Inc.,(Pink Sheets: ... company, announced today that A. Marc Rocca, 42, ... The Company,s mission is to identify, evaluate ... and healthcare solutions, and then,seek to capture and ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... North America in Deal Valued at up ... to $185 ... 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed announced ... to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) outside ...
... ultrasound-guided fine needle to biopsy lymph nodes could spare ... to undergo unnecessary and sometimes unpleasant surgery to verify ... , In a study presented today (Wednesday) at the ... that the less invasive technique produced a false positive ...
... Barcelona, Spain: New research has yielded a clearer picture ... the treatment of colon cancer, bringing closer the day ... spared it, while those that will, get the more ... other solid tumours, doctors plan treatment of colon cancer ...
... to use for older people is the focus of a ... in funding in the latest round of the Australian Research ... design researcher Dr Thea Blackler, is one of 24 projects ... announcement tops off a successful week for QUT research, with ...
Cached Medicine News:Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: